Amgen Says Sanofi Contradicting Itself In High Court IP Feud
Biotechnology giant Amgen has urged the U.S. Supreme Court not to "distort enablement law" as justices review a Federal Circuit decision axing patents on its cholesterol drug Repatha, arguing that Sanofi...To view the full article, register now.
Already a subscriber? Click here to view full article